Up until now, many therapeutic agents could only be delivered using inhaled methods, limiting their dosing accuracy, efficacy and safety. Hillhurst’s proprietary GLASS platform enables the novel oral delivery of these agents, making them more safe, convenient, accurate, and suitable for at-home administration.  We’ve developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson’s disease, and acute pain.

We are committed to realizing the full medical potential of hard to deliver inhaled therapeutics for patients in need. We are driven by a sense of urgency to treat debilitating diseases with limited treatment options. Therapeutics which previously had to be inhaled can now be delivered by Hillhurst’s novel oral liquid delivery applications.